Viva Biotech’s $194 Million Initial Public Offering

O’Melveny represented Viva Biotech on the listing

Viva Biotech (1873.HK) executed its $194 million initial public offering and listing on the Main Board of the Hong Kong Stock Exchange.

Viva Biotech’s HK IPO was very successful in the HK capital market with an over-subscription of HK public offer shares of over 100 times. O’Melveny also represented Viva Biotech in its US$31 million pre-IPO investment in June 2018.

China International Capital Corporation Hong Kong Securities Limited (CICC) was the sole sponsor and CICC, J.P. Morgan, and Normura were the joint global coordinators. The joint bookrunners included Bank of China International, China Renaissance, and Haitong International Securities.

Based in Shanghai, Viva Biotech operates a leading innovation-driven technology platform to support clients’ pre-clinical drug discovery. Viva Biotech is well known for its cutting-edge technologies in protein science, structure based drug design, fragment based drug design, affinity selection mass spectrometry screening technology, and membrane protein targeted drug discovery. In addition, Viva Biotech is innovative for its “equity for services” business model, which has incubated 30 early stage research and development projects, and plans to incubate more projects in the future.

The O’Melveny team was led by partners Ke Geng (Picture), Ke Zhu, and Edwin Kwok. The team included counsel Vincent Lin, associates Ling Zhang, Claire Huang, and Xiaoyu Xu, trainee solicitors Edward Poon, Valarie Tsui, and Hilda Leung, and legal assistant Peiji Yu. Partner Eric Sibbitt and counsel Adam Ajlouni provided 40 Act advice, and counsel Anita Choi provided tax advice.

Involved fees earner: Adam Ajlouni – O’Melveny & Myers LLP; Anita Choi – O’Melveny & Myers LLP; Ke Geng – O’Melveny & Myers LLP; Claire Huang – O’Melveny & Myers LLP; Edwin Kwok – O’Melveny & Myers LLP; Vincent Lin – O’Melveny & Myers LLP; Eric Sibbitt – O’Melveny & Myers LLP; Xiaoyu Xu – O’Melveny & Myers LLP; Ling Zhang – O’Melveny & Myers LLP; Ke Zhu – O’Melveny & Myers LLP;

Law Firms: O’Melveny & Myers LLP;

Clients: Viva Biotech Holdings;


Author: Michael Patrini